Sir Peter MacCallum Department of Oncology - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 5 of 5
  • Item
    Thumbnail Image
    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
    Blombery, P ; Birkinshaw, RW ; Nguyen, T ; Gong, J-N ; Thompson, ER ; Xu, Z ; Westerman, DA ; Czabotar, PE ; Dickinson, M ; Huang, DCS ; Seymour, JF ; Roberts, AW (WILEY, 2019-09)
  • Item
    Thumbnail Image
    Revisiting acquired aplastic anaemia: current concepts in diagnosis and management
    Clucas, DB ; Fox, LC ; Wood, EM ; Hong, FS ; Gibson, J ; Bajel, A ; Szer, J ; Blombery, P ; McQuilten, ZK ; Hiwase, D ; Firkin, F ; Cole-Sinclair, MF ; Firkin, F ; Badoux, X ; Bajel, A ; Blombery, P ; Cole, C ; Cole-Sinclair, M ; Fox, L ; Forsyth, C ; Gibson, J ; Hiwase, D ; Hong, F ; Johnston, A ; McQuilten, Z ; Mills, T ; Opat, S ; Roncolato, F ; Szer, J ; Wood, E (WILEY, 2019-02)
    Acquired aplastic anaemia is a rare, serious, immunologically mediated bone marrow failure syndrome, characterised by marrow hypoplasia of varying severity and significant pancytopenia. Careful attention and investigation, including molecular testing, is required to confirm the diagnosis and exclude other mimicking conditions, such as inherited bone marrow failure syndromes. In a proportion of patients, the disease evolves to myelodysplasia or acute myeloid leukaemia and in some there is an association with paroxysmal nocturnal haemoglobinuria. The disease has a major impact on patient quality of life. Haemopoietic stem/progenitor cell transplantation for eligible patients with an available donor is the only current curative therapy. Other patients may receive immunosuppression, most commonly with anti-thymocyte globulin and cyclosporin. An initial response to immunosuppression is often encouraging, but relapse is common. Supportive care, including management of transfusion requirements and infections, is central to management. Promising new diagnostic tools and emerging therapies will likely transform approaches to this important, chronic and life-threatening condition.
  • Item
    Thumbnail Image
    Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
    Birkinshaw, RW ; Gong, J-N ; Luo, CS ; Lio, D ; White, CA ; Anderson, MA ; Blombery, P ; Lessene, G ; Majewski, IJ ; Thijssen, R ; Roberts, AW ; Huang, DCS ; Colman, PM ; Czabotar, PE (NATURE PUBLISHING GROUP, 2019-06-03)
    Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing therapy. To understand the molecular basis of this acquired resistance we describe the crystal structures of venetoclax bound to both BCL-2 and the G101V mutant. The pose of venetoclax in its binding site on BCL-2 reveals small but unexpected differences as compared to published structures of complexes with venetoclax analogues. The G101V mutant complex structure and mutant binding assays reveal that resistance is acquired by a knock-on effect of V101 on an adjacent residue, E152, with venetoclax binding restored by a E152A mutation. This provides a framework for considering analogues of venetoclax that might be effective in combating this mutation.
  • Item
    Thumbnail Image
    Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
    Gregory, GP ; Dickinson, M ; Yannakou, CK ; Wong, J ; Blombery, P ; Corboy, G ; Kats, L ; Crozier, TME ; Kumar, B ; Prince, HM ; Opat, SS ; Shortt, J (LIPPINCOTT WILLIAMS & WILKINS, 2019-04)
  • Item
    Thumbnail Image
    CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing
    Markham, JF ; Yerneni, S ; Ryland, GL ; Leong, HS ; Fellowes, A ; Thompson, ER ; De Silva, W ; Kumar, A ; Lupat, R ; Li, J ; Ellul, J ; Fox, S ; Dickinson, M ; Papenfuss, AT ; Blombery, P (Nature Publishing Group, 2019-04-23)
    Next Generation Sequencing is now routinely used in the practice of diagnostic pathology to detect clinically relevant somatic and germline sequence variations in patient samples. However, clinical assessment of copy number variations (CNVs) and large-scale structural variations (SVs) is still challenging. While tools exist to estimate both, their results are typically presented separately in tables or static plots which can be difficult to read and are unable to show the context needed for clinical interpretation and reporting. We have addressed this problem with CNspector, a multi-scale interactive browser that shows CNVs in the context of other relevant genomic features to enable fast and effective clinical reporting. We illustrate the utility of CNspector at different genomic scales across a variety of sample types in a range of case studies. We show how CNspector can be used for diagnosis and reporting of exon-level deletions, focal gene-level amplifications, chromosome and chromosome arm level amplifications/deletions and in complex genomic rearrangements. CNspector is a web-based clinical variant browser tailored to the clinical application of next generation sequencing for CNV assessment. We have demonstrated the utility of this interactive software in typical applications across a range of tissue types and disease contexts encountered in the context of diagnostic pathology. CNspector is written in R and the source code is available for download under the GPL3 Licence from https://github.com/PapenfussLab/CNspector. A server running CNspector loaded with the figures from this paper can be accessed at https://shiny.wehi.edu.au/jmarkham/CNspector/index.html.